There is no law against prisoner organ donation; however, the transplant community has discouraged use of prisoners organs since the early 1990s due to concern over prisons high-risk environment for infectious diseases. Physicians and ethicists also criticize the idea because a prisoner is not able to consent to the procedure in a free and non-coercive environment, especially if given inducements to participate. However, with modern testing advances to more safely rule out infectious disease and by ensuring that there are no incentives offered to participate, some have argued that prisoners can now voluntarily consent to organ donation just as they can now consent to medical procedures in general. With careful safeguards, and with over 2 million prisoners in the U.S., they reason that prisoners can provide a solution for reducing organ shortages in the U.S.While some have argued that prisoner participation would likely be too low to make a difference, one Arizona program started by former Maricopa County Sheriff Joe Arpaio encourages inmates to voluntarily sign up to donate their heart and other organs. As of 2015, there have been over 16,500 participants. Similar initiatives have been started in other US states. In 2013, Utah became the first state to allow prisoners to sign up for organ donation upon death. Religious viewpoints
There are several different religions that have different perspectives. Islam has a conflicting view regarding the issue, with half believing that it is against the religion.
DTaP-IPV vaccine is a combination vaccine whose full generic name is diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine (IPV).It is also known as DTaP/IPV, dTaP/IPV, DTPa-IPV, or DPT-IPV. It protects against the infectious diseases diphtheria, tetanus, pertussis, and poliomyelitis.Branded formulations marketed in the USA are Kinrix from GlaxoSmithKline and Quadracel from Sanofi Pasteur.Repevax is available in the UK.Within Japan, the formulation is called  四種混合（shishukongou - "mixture of 4"). Astellas markets it under the クアトロバック (Quattro-back) formulation, while another is available from Mitsubishi Tanabe Pharma named テトラビック (Tetrabic). A previous product by Takeda Pharmaceutical Company has been withdrawn by the company. == References ==